Vaxonella
| Source | SynBio Database |
|---|---|
| Organization | Prokarium |
| Website URL | www.prokarium.com/#technology-section |
| Market status | On the market + Under Development |
| Industry | Health |
| Value chain stage | Finished Product |
| Intended consumer | Commercial |
| Production process | Closed Production |
| Business models | B2C |
| Product categories | Medical Treatment |
| Biotech components | Bacteria |
| Organization type(s) | Private Company |
| Funding types | Venture Capital |
| Known funding amount | $12,600,000 USD |
| Country of production | UK |
| Notes | Acquired from Emergent Biosolutions in 2012 The vaccine uses an attenuated strain of Salmonella enterica that is genetically engineered to express antigens from the Salmonella Typhi strain, ZH9. |
| Additional link #1 | labiotech.eu/medical/oral-vaccines-typhoid-… |